Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Igor Rubinshteyn

Orthopaedic Surgery Brooklyn, NY Medical Doctor

NPI 1235292574 CMS profile 328483

3049 Ocean Pkwy Fl 2, Brooklyn, NY 11235

Open in the dashboard

General payments

$3,474

69 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Igor Rubinshteyn of Brooklyn, NY is reported in the CMS Open Payments database as having received $3,474 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $286 10
2024 General $1,214 13
2023 General $184 6
2022 General $428 8
2021 General $846 12
2020 General $215 10
2019 General $301 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Igor Rubinshteyn
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Igor Rubinshteyn were reported at $286. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Igor Rubinshteyn Orthopaedic Surgery median Middle half National median
2019 $301 $644 $140–$2,844 $163
2020 $215 $312 $75–$1,860 $114
2021 $846 $520 $117–$2,495 $132
2022 $428 $598 $128–$2,731 $149
2023 $184 $461 $128–$2,264 $160
2024 $1,214 $497 $134–$2,475 $164
2025 $286 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pacira Pharmaceuticals Incorporated $853 5 payments
  2. Fidia Pharma USA Inc. $718 10 payments
  3. Orthofix Medical, Inc. $649 15 payments
  4. Sanara MedTech Inc. $225 1 payment
  5. Horizon Therapeutics plc $178 10 payments
  6. Flexion Therapeutics, Inc. $146 5 payments
  7. EMD Serono, Inc. $125 1 payment
  8. Zimmer Biomet Holdings, Inc. $99 1 payment
  9. Vertex Pharmaceuticals Incorporated $89 3 payments
  10. DePuy Synthes Sales Inc. $88 4 payments
  11. Other $305 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,170 65 payments
  2. Travel and Lodging $710 2 payments
  3. Long term medical supply or device loan $495 1 payment
  4. Education $99 1 payment
Products named General payments · program years 2019–2025
  1. Iovera $853 5 payments
  2. Physio-Stim $749 18 payments
  3. RICHPLAT ORTHO PRP SYSTEM $495 1 payment
  4. CellerateRx $225 1 payment
  5. Zilretta $146 5 payments
  6. Mavenclad $125 1 payment
  7. HYMOVIS $112 6 payments
  8. TRILURON $109 6 payments
  9. Persona $99 1 payment
  10. PENNSAID $92 5 payments
  11. Other $809 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

480

Median for Orthopedic Surgery: 203

Drug cost

$22,169

Median for Orthopedic Surgery: $1,433

Branded share of claims

6.7%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 168 $19,176
Diclofenac Potassium Generic 14 $1,657
Celecoxib Generic 67 $564
Meloxicam Generic 142 $373
Ibuprofen Generic 29 $184
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 32 $170
Tramadol Hcl Generic 28 $44

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$252,891

Of which drugs: $35,824

Medicare patients

596

Average age 78

Services billed

12,591

406 women, 190 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 66%
Ischemic heart disease 55%
Depression 42%
Heart failure 30%
COPD 26%
Osteoporosis 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 82 451 $26,085
Hyaluronan or derivative, triluron, for intra-articular injection, 1 mg J7332 Office 12 660 $5,369
Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg J7328 Office 14 8,904 $4,021
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 120 454 $349

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $11
$11 — —
Prolia
  • Amgen Inc. $11
$11 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record